<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pediatric procedural sedation: Pharmacologic agents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pediatric procedural sedation: Pharmacologic agents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pediatric procedural sedation: Pharmacologic agents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph P Cravero, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark G Roback, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anne M Stack, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Adrienne G Randolph, MD, MSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James F Wiley, II, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H7977200">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         A wide range of short-acting sedative-hypnotic and analgesic medications are available for pediatric procedural sedation [
         <a href="#rid1">
          1-3
         </a>
         ]. Many of these agents have multiple routes of administration. The choice of drug is based upon the type of procedure and the patient's underlying medical condition. Procedures that are not painful but require the child to remain still can usually be performed with sedation alone. Children undergoing painful procedures require analgesia as well as sedation.
        </p>
        <p>
         This topic will discuss the properties of agents commonly used for procedural sedation in children.
        </p>
        <p>
         Assessment, preparation, and proper performance of procedural sedation outside of the operating room, including selection of medications for pediatric procedural sedation, are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16900.html" rel="external">
          "Procedural sedation in children: Preparation"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2043631523">
         <span class="h1">
          TOPIC SCOPE
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic discusses pharmacologic agents for emergency and scheduled (elective) pediatric procedural sedation performed by sedation providers from a variety of disciplines including general and pediatric emergency medicine, pediatric critical care medicine, pediatric hospital medicine, and general pediatrics.
        </p>
        <p class="headingAnchor" id="H7977207">
         <span class="h1">
          SEDATIVE-HYPNOTIC AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         These drugs provide sedation, motion control, anxiolysis, and to varying degrees, amnesia but (with the exception of
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         ) do
         <strong>
          not
         </strong>
         provide analgesia. The properties of commonly used agents for pediatric procedural sedation are provided and summarized in the tables  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         When used for procedural sedation in children, these agents should
         <strong>
          only
         </strong>
         be administered by properly trained and experienced clinicians. All children require careful pre-sedation evaluation. The clinician should develop a sedation plan that provides appropriate targeted level of sedation (mild, moderate, dissociative, or deep) as determined by patient characteristics, anticipated degree of procedural pain, and procedural requirements. Appropriate monitoring, personnel, and equipment must also be in place during the sedation. (See
         <a class="medical medical_review" href="/z/d/html/16900.html" rel="external">
          "Procedural sedation in children: Preparation", section on 'Pre-sedation evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach", section on 'Performing procedural sedation'
         </a>
         .)
        </p>
        <p>
         Selection of medications for pediatric procedural sedation is determined by patient factors, anticipated degree of pain, and type of procedure and is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications", section on 'Choice of sedative agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3220172">
         <span class="h2">
          Propofol
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          Propofol
         </a>
         is a nonopioid, nonbarbiturate sedative hypnotic that has historically been extensively used by anesthesiologists and intensivists as an induction agent for general anesthesia and as a sedative in intensive care units [
         <a href="#rid4">
          4,5
         </a>
         ]. Over the past two decades, propofol has also been used extensively for procedural sedation in sedation units, emergency departments, and radiology suites [
         <a href="#rid6">
          6-11
         </a>
         ]. The decision to use propofol and whether it is used with other agents (eg,
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         ) should depend on the duration and the nature of the procedure being performed.
        </p>
        <p>
         Practitioners who choose to use
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         alone or in combination with other medications for brief procedural sedation outside of the operating room must vigilantly adhere to protocols that include careful monitoring with capnography as well as pulse oximetry [
         <a href="#rid12">
          12
         </a>
         ] . Use must be consistent with hospital guidelines and protocols, local regulations, and the practitioner's privilege delineation. In some regions, propofol is
         <strong>
          only
         </strong>
         approved for use by physicians with special airway training, such as intensivists and emergency physicians with specialized pediatric procedural sedation training. Clinicians should check local recommendations for propofol administration.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration –
         </strong>
         When used for prolonged sedation (eg, during magnetic resonance imaging), a continuous intravenous infusion of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         at a starting dose of 150 mcg/kg per minute is frequently effective [
         <a href="#rid2">
          2,13
         </a>
         ]. The infusion dose is then gradually increased as needed to achieve adequate sedation up to a maximum dose of 250 mcg/kg per minute. Administering
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         1 to 2 mcg/kg IV bolus prior to propofol infusion may reduce the total amount of propofol needed for sedation and has been associated with fewer adverse events [
         <a href="#rid14">
          14-16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For brief procedures,
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         may also be administered as a continuous infusion or as an initial intravenous (IV) bolus dose of 1 to 1.5 mg/kg (2 mg/kg in infants and children between six months and two years of age) [
         <a href="#rid13">
          13
         </a>
         ]. When propofol is combined with other agents (eg,
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         [
         <a href="#rid14">
          14
         </a>
         ], or
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         ), the initial bolus dose of 0.5 to 1 mg/kg is suggested. Repeated doses of 0.5 mg/kg of IV propofol may be given every three to five minutes, up to a maximum total dose of 3 mg/kg, as needed to achieve the desired effect. Relative to a continuous infusion, bolus dosing of propofol increases the risk of exceeding the desired level of sedation and is associated with a higher likelihood of respiratory depression, bradycardia, and hypotension, especially when combined with opioid medications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hypovolemic patients should receive IV fluids to correct volume status prior to
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         sedation. For children with reduced cardiac output, attempts should be made to improve cardiac performance prior to sedation and dosing should be minimized. In these patients, propofol sedation should only be provided by clinicians with significant experience sedating children with heart disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          Propofol
         </a>
         causes pain during IV administration that can be reduced by IV pretreatment with 0.5 mg/kg of systemic
         <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">
          lidocaine
         </a>
         injected into the vein with a tourniquet applied for one minute, or by administration of
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         or an opioid prior to propofol [
         <a href="#rid2">
          2
         </a>
         ]. Pain is also lessened by injecting into an antecubital rather than a hand vein.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefits
         </strong>
         – Compared with other commonly used agents,
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         has the fastest onset of action and one of the shortest recovery times  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ). Propofol reduces intracranial pressure, making it a good choice in hemodynamically stable patients with head trauma. Studies indicate high efficacy for successful completion of diagnostic imaging and, when combined with
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         , a variety of painful procedures [
         <a href="#rid17">
          17-19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Because of the rapid onset of action and high potency of the drug, it can rapidly achieve a greater depth of sedation than intended, including general anesthesia, especially when given in bolus doses [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Minor adverse effects requiring routine intervention by appropriately trained providers occur in approximately 2 to 5 percent of children undergoing
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         sedation and include respiratory depression, apnea, and hypotension [
         <a href="#rid6">
          6,11,21-23
         </a>
         ]. Major events such as respiratory arrest requiring endotracheal intubation, pulmonary aspiration, and cardiorespiratory arrest have all been described but occur rarely when sedation is performed by well-trained physicians as part of an organized sedation service [
         <a href="#rid7">
          7,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a systematic review of 20 trials and 40 observational studies of approximately 17,000 children undergoing sedation outside of the operating room, use of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         was associated with the following adverse events [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Respiratory events
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Oxygen desaturation: 9 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Apnea: 2 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Laryngospasm: 0.2 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Unplanned intubation: 0.02 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypotension: 15 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bradycardia: 0.1 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Hypotension was recorded as transient in the majority of cases; no adverse sequela of hypotension was documented. No patient required treatment for bradycardia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a separate study of almost 50,000 pediatric sedations outside of the operating room, rates of adverse events for
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         per 10,000 sedations were as follows [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Airway obstruction: 432/10,000
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Oxygen desaturation (&lt;90 percent for &gt;30 seconds): 154/10,000
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         &gt;30 percent change in heart rate, blood pressure, or respiratory rate: 61/10,000
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Apnea: 31/10,000
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Laryngospasm: 21/10,000
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         This study also documented four cases of aspiration and two cardiac arrests.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although evidence is limited, the addition of an opioid (eg,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         ) to
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         sedation appears to increase the risk of respiratory events. As an example, in a trial that included 59 children undergoing fracture reduction, oxygen desaturation and requirement for respiratory maneuvers occurred more often in patients receiving propofol and fentanyl (31 percent) compared with
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         (7 percent) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and precautions
         </strong>
         – Formulations of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         contain egg lecithin, egg yolk phospholipids, and soybean oil. The manufacturer's instructions advise against the use of this agent in patients with egg allergy. However, observational evidence suggests that propofol may be used safely in patients with egg, soy, and peanut allergies (see
         <a class="medical medical_review" href="/z/d/html/2406.html" rel="external">
          "Management of food allergy: Avoidance", section on 'Lipid emulsions'
         </a>
         ). Thus, we do not view the history of allergy to these foods as a contraindication to the use of propofol. While no special precautions are recommended for the administration of propofol to most patients with soy or egg allergy, use of an alternate anesthetic or a small trial dose of propofol prior to full dose administration is an option for those patients with more severe soy or egg allergy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prolonged
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         infusions in critically ill pediatric patients have been associated with the propofol infusion syndrome, an acute refractory bradycardia that progresses to asystole in combination with metabolic acidosis, rhabdomyolysis, hyperlipidemia, and/or fatty liver. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Propofol-related infusion syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3220179">
         <span class="h2">
          Dexmedetomidine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          Dexmedetomidine
         </a>
         is a selective alpha-2 adrenergic receptor agonist that offers potent sedative effects along with some analgesia. Unlike most sedatives, it causes minimal respiratory depression in children. Studies in children support dexmedetomidine as an effective sedative that maintains spontaneous ventilation and preserves upper airway tone, which makes it a desirable choice for procedural sedation [
         <a href="#rid26">
          26-29
         </a>
         ]. In healthy children, dexmedetomidine has been found to be generally safe and effective for nonpainful procedures (eg, neuroimaging) [
         <a href="#rid13">
          13
         </a>
         ]. In some sedation services, dexmedetomidine is frequently used to sedate for diagnostic imaging [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intravenous dose (infants &gt;1 month old up to adolescents)
         </strong>
         – When
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         is given intravenously for sedation in children, titration to effect is often required, and effective dosing can vary widely in individual patients. The dosing regimen typically consists of a loading dose and maintenance of sedation with a continuous infusion  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid29">
          29
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Loading dose (
         </strong>
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         <strong>
          as sole medication)
         </strong>
         – Initial loading dose 1 to 2 mcg/kg over 10 minutes; if child is not sedated after 10 minutes, give a repeat dose of 0.5 to 1 mcg/kg over 10 minutes (lower dose if patient has some effect but still requires more sedation; higher dose if not much effect from the initial dose). The total maximum loading dose is 3 mcg/kg.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         When IV
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         is used as the sole agent for sedation, a loading dose of 1.5 to 2 mcg/kg is effective for most children. However, some children may require doses up to 3 mcg/kg to successfully complete the procedure [
         <a href="#rid31">
          31
         </a>
         ]. Of note, self-limited bradycardia commonly occurs at doses above 2 mcg/kg but usually does not require intervention.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         When
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         is given by itself for sedation during imaging or minor procedures, a loading dose of 1.5 mcg/kg over 10 minutes is effective in about two-thirds of pediatric patients (1 month to 18 years of age). Lower initial doses (eg, 0.5 to 1 mcg/kg) are associated with a lower rate of success and a requirement for repeat loading doses. Higher doses (eg, 2 mcg/kg to 3 mcg/kg over 10 minutes) increase the rate of successful sedation to &gt;90 percent of patients [
         <a href="#rid31">
          31
         </a>
         ]. Self-limited bradycardia commonly occurs at doses above 2 mcg/kg but usually does not require intervention. When administered with other medications, the effective dose of dexmedetomidine is decreased.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Loading dose (
         </strong>
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         <strong>
          combined with another agent [eg,
         </strong>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         <strong>
          ,
         </strong>
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         <strong>
          ,
         </strong>
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         <strong>
          , or opioid analgesia])
         </strong>
         – Give a loading dose of 0.5 to 1 mcg/kg over 10 minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Maintenance dose
         </strong>
         – After the loading dose start a continuous infusion of 1 to 2 mcg/kg/hour [
         <a href="#rid17">
          17,31-33
         </a>
         ]. Titrate to desired clinical effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Alternatively, administration of
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         (0.1 mg/kg, maximum dose 2 mg) will decrease the required dosing of
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         (eg, initial IV bolus of 0.5 to 1 mcg/kg over 10 minutes followed by a continuous infusion of 0.5 to 1 mcg/kg per hour is often effective).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intranasal (IN) dose
         </strong>
         – IN
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         doses of 2.5 to 4 mcg/kg (maximum single dose 200 mcg) have been shown to be effective for nonpainful procedures such as computed tomography or echocardiography [
         <a href="#rid34">
          34-39
         </a>
         ]. In a small series of 42 children with autism, a dose of 4 mcg/kg in conjunction with desensitization and nonpharmacologic interventions has also shown efficacy for minimally invasive procedures such as blood draws, immunizations, and balloon gastrostomy button replacement [
         <a href="#rid38">
          38
         </a>
         ]. However, most evidence on comparative effectiveness of IN dexmedetomidine with other commonly used agents is of low quality or is lacking [
         <a href="#rid37">
          37
         </a>
         ]. In addition, further study is needed to determine the optimal dosing for IN dexmedetomidine. (See
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications", section on 'No intravenous access'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications", section on 'Sedation for other nonpainful procedures'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Buccal dose
         </strong>
         : Based upon perioperative studies, buccal administration of 3 to 4 mcg/kg results in moderate sedation without reported respiratory complications [
         <a href="#rid40">
          40-42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefits
         </strong>
         – Intravenous
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         provides effective pediatric sedation with a low potential for respiratory depression [
         <a href="#rid43">
          43
         </a>
         ]. It is most effective for sedation of noninvasive, nonpainful procedures. Although onset of action is slower than other IV agents with a somewhat longer recovery time, recovery agitation is minimal  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ). Dexmedetomidine has also achieved high efficacy for successful completion of nonpainful diagnostic studies in children with autism and other behavioral disorders [
         <a href="#rid13">
          13,38,44
         </a>
         ]. In addition, dexmedetomidine is particularly useful when weaning mechanically ventilated children from ventilators since it is not associated with respiratory depression [
         <a href="#rid45">
          45,46
         </a>
         ]. By contrast, respiratory depression during sedation with dexmedetomidine has been described in adults and may be more frequent in that population. (See
         <a class="medical medical_review" href="/z/d/html/94529.html" rel="external">
          "Monitored anesthesia care in adults", section on 'Dexmedetomidine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Notably, of all the commonly used sedatives and anesthetics,
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         is the only agent that may be neuroprotective for the development of neuroapoptosis or neurocognitive impairment in animal models, while other agents have been shown to accentuate these effects [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Important adverse effects
         </strong>
         – In a large prospective observational study of over 13,000 children who received IV
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         for sedation, serious adverse events, primarily laryngospasm, occurred in 0.3 percent of patients [
         <a href="#rid43">
          43
         </a>
         ]. Overall adverse events (which included events that spontaneously resolved or were easily managed by the sedation provider) were seen in approximately 4 percent of patients, with the most common event being an unexpected change in heart rate or blood pressure of &gt;30 percent from baseline, agitation, delirium, or transient oxygen desaturation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hypertension has been described in up to 5 percent of patients receiving IV
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         . This adverse effect is associated with younger patient age, higher dose, and multiple boluses of the drug [
         <a href="#rid33">
          33
         </a>
         ]. Hypertension is dose-related and typically resolves without specific treatment or with discontinuation of the infusion [
         <a href="#rid32">
          32,33
         </a>
         ]. Hypotension during the initial bolus dose of dexmedetomidine is also dose-related and is usually reversed with a fluid bolus. By contrast, profound bradycardia has been described in patients who have conduction system pathology or who are receiving atrioventricular (AV) nodal-slowing medications such as
         <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">
          digoxin
         </a>
         [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a systematic review of 19 trials (2137 patients), children receiving IN
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         administered in doses ranging from 1 to 4 mcg/kg for nonpainful procedures had low rates of bradycardia (2.2 percent) and hypotension (1.2 percent), and no patient required resuscitative measures [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and precautions
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          Dexmedetomidine
         </a>
         should be avoided in children who are receiving medicines with rate-slowing action on the AV node (eg,
         <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">
          digoxin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12643" href="/z/d/drug information/12643.html" rel="external">
          nifedipine
         </a>
         ), those with cardiac conduction system pathology, and those in whom increased pulmonary artery pressure or decreased cardiac output are unlikely to be well tolerated (eg, right-sided heart failure, septic shock) unless it is provided by clinicians with training and expertise in cardiac anesthesia [
         <a href="#rid49">
          49,50
         </a>
         ]. Administration of
         <a class="drug drug_pediatric" data-topicid="13338" href="/z/d/drug information/13338.html" rel="external">
          glycopyrrolate
         </a>
         to treat bradycardia caused by dexmedetomidine has been associated with severe hypertension [
         <a href="#rid51">
          51
         </a>
         ]. Thus, the use of glycopyrrolate and other anticholinergic agents (eg,
         <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">
          atropine
         </a>
         ) should be avoided in these patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2606114">
         <span class="h2">
          Etomidate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          Etomidate
         </a>
         is an imidazole, nonbarbiturate hypnotic agent with an ultra-short onset of action (5 to 30 seconds). In healthy patients (American Society of Anesthesia class I or II)  (
         <a class="graphic graphic_table graphicRef113973" href="/z/d/graphic/113973.html" rel="external">
          table 3
         </a>
         ), duration of effect is also short (5 to 15 minutes) and depends upon the initial dose. Rapid recovery results from drug redistribution. The duration of effect is prolonged in patients with hepatic or renal dysfunction.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          Etomidate
         </a>
         is given as an IV bolus dose of 0.1 to 0.3 mg/kg [
         <a href="#rid2">
          2
         </a>
         ]. Repeated doses of 0.05 mg/kg may be given every five minutes up to a maximum total dose of 0.6 mg/kg to achieve the desired effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          Etomidate
         </a>
         causes pain during IV administration that can be reduced by IV pretreatment with 0.5 mg/kg of systemic
         <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">
          lidocaine
         </a>
         that is injected into the vein one minute prior to etomidate with a tourniquet applied. Pain is also lessened by injecting into an antecubital rather than a hand vein.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefits
         </strong>
         – Rapid onset of action and recovery with few residual effects make
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         useful for sedation during brief nonpainful procedures, especially for children who require ongoing clinical assessment of consciousness (eg, patients with head injury)  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ). Etomidate also reduces intracranial pressure and maintains hemodynamic stability [
         <a href="#rid13">
          13
         </a>
         ]. Thus, it is a good choice for sedating patients in whom cardiovascular status is uncertain or compromised (eg, multiple system trauma patients). Etomidate is an ultra-short-acting drug that is best suited to sedation for very brief procedures [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications", section on 'Intravenous medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – The frequency of adverse events when
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         is given as a single agent for pediatric procedural sedation is approximately 1 percent. The most commonly reported adverse events include respiratory depression, vomiting, and nonepileptiform myoclonus [
         <a href="#rid2">
          2,13,53
         </a>
         ]. Adverse events may be more frequent when etomidate is combined with an opioid [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The frequency of nonepileptiform myoclonus in children receiving
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         as a single agent for nonpainful procedures appears to be lower than in adults (&lt;1 percent versus up to 80 percent, respectively) [
         <a href="#rid53">
          53
         </a>
         ]. In adults, small trials suggest that premedication with
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         0.15 mg/kg,
         <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">
          magnesium sulfate
         </a>
         , or etomidate 0.03 to 0.05 mg/kg significantly reduces the frequency of myoclonus. However, given the lower frequency of myoclonus in children, the routine administration of any of these drugs appears unwarranted. (See
         <a class="medical medical_review" href="/z/d/html/139217.html" rel="external">
          "Procedural sedation in adults in the emergency department: Medication selection, dosing, and discharge criteria", section on 'Etomidate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If myoclonus occurs during pediatric procedural sedation, IV
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         is suggested [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and precautions
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          Etomidate
         </a>
         inhibits 11-beta hydroxylase, an enzyme important for adrenal steroid production, and is contraindicated in patients with known adrenal insufficiency. Adrenal suppression from single doses of etomidate has not been associated with any negative outcomes in healthy children undergoing procedural sedation. Acute adrenal insufficiency and increased mortality have been associated with single doses of etomidate in children with sepsis. (See
         <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">
          "Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Airway and breathing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7977214">
         <span class="h2">
          Midazolam
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         is a short-acting benzodiazepine with a rapid onset of action when given via IV [
         <a href="#rid2">
          2
         </a>
         ]. It has good anxiolytic, amnestic, and muscle relaxant properties and has been frequently used to provide mild sedation in children or combined with
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          dexmedetomidine
         </a>
         to achieve moderate sedation [
         <a href="#rid2">
          2,3,13
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         is water soluble and can be given by parenteral (IV or intramuscular), rectal (PR), intranasal, sublingual (SL), or oral (PO) routes. Doses, onset of action, and duration of effect will vary depending upon patient age and the route of administration  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid2">
          2,3,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When compared with PR, SL, or PO administration, intranasal
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         has the most rapid onset of action and shortest recovery time  (
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. However, intranasal midazolam can be very irritating for some children. Pretreatment with
         <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">
          lidocaine
         </a>
         spray (10 mg per puff) one minute prior to intranasal administration decreases nasal mucosal irritation [
         <a href="#rid55">
          55
         </a>
         ]. An atomizer device delivers midazolam as a fine mist, which results in better nasal mucosa absorption and comfort with reduction of sneezing and cough when compared with direct instillation [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefits
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         has strong amnestic properties and is an effective anxiolytic in most children [
         <a href="#rid2">
          2,3,13
         </a>
         ]. The many potential routes of administration permit its use in children without vascular access. When used as the sole agent for sedation with proper dosing, respiratory depression is rare. Midazolam has a shorter duration of action than
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13143" href="/z/d/drug information/13143.html" rel="external">
          chloral hydrate
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="13307" href="/z/d/drug information/13307.html" rel="external">
          Flumazenil
         </a>
         is an effective reversal agent for the few patients who develop significant respiratory depression or apnea after sedation with
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         . Flumazenil should
         <strong>
          not
         </strong>
         be used in patients with seizure disorders or those who receive benzodiazepines on a chronic basis because of the risk of precipitating seizures or withdrawal symptoms, respectively. The use of flumazenil to reverse adverse effects of benzodiazepines, including dosing and redosing recommendations, is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/314.html" rel="external">
          "Benzodiazepine poisoning", section on 'Role of antidote (flumazenil)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         can cause respiratory depression and apnea, especially when combined with opioid medications such as
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         [
         <a href="#rid2">
          2,3
         </a>
         ]. For example, of 130 children receiving midazolam and fentanyl for orthopedic procedures in a randomized trial, hypoxia occurred in one-quarter of patients, 20 percent received supplemental oxygen, 12 percent needed breathing cues, and laryngospasm was described in one patient [
         <a href="#rid58">
          58
         </a>
         ]. (See
         <a class="local">
          'Fentanyl'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Paradoxical reactions, including inconsolable crying, hyperactivity, and aggressive behavior may occur in approximately 1 to 3 percent of patients when
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         is use as a single agent [
         <a href="#rid59">
          59-61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Both respiratory depression and paradoxical reactions can be reversed with
         <a class="drug drug_pediatric" data-topicid="13307" href="/z/d/drug information/13307.html" rel="external">
          flumazenil
         </a>
         [
         <a href="#rid59">
          59,62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/314.html" rel="external">
          "Benzodiazepine poisoning", section on 'Role of antidote (flumazenil)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         is inferior as a sedative agent for computed tomography when compared with short-acting barbiturates. (See
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications", section on 'No intravenous access'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and precautions
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         has mild negative inotropic effects and should be used with caution in children with underlying myocardial depression [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2606931">
         <span class="h2">
          Short-acting barbiturates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Barbiturates are central gamma-aminobutyric acid (GABA) agonists. In the past, these agents were often used to sedate children. More recently, they have been replaced by other agents with equivalent or better efficacy, shorter recovery times, and fewer adverse events.
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          Pentobarbital
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12594" href="/z/d/drug information/12594.html" rel="external">
          methohexital
         </a>
         , and thiopental (
         <strong>
          not
         </strong>
         available in the United States or Canada) are the barbiturates most commonly used to sedate children [
         <a href="#rid63">
          63,64
         </a>
         ]. Of these agents, pentobarbital has the best efficacy and fewest adverse effects. (See
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications", section on 'No intravenous access'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
         – The initial IV dose of
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         is 1 to 2 mg/kg (maximum single dose 100 mg). This dose can be repeated every three to five minutes up to a maximum total dose of 6 mg/kg (maximum total dose 600 mg). Patients receiving concurrent barbiturate therapy (eg,
         <a class="drug drug_pediatric" data-topicid="12698" href="/z/d/drug information/12698.html" rel="external">
          phenobarbital
         </a>
         ) may require higher total doses up to 9 mg/kg to achieve adequate sedation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The PO or PR dose of
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         varies by age. Children younger than four years of age can receive 3 to 6 mg/kg PO or PR (maximum single dose 100 mg). Children four years of age and older are given 1.5 to 3 mg/kg PO or PR (maximum single dose 100 mg).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When used for pediatric procedural sedation,
         <a class="drug drug_pediatric" data-topicid="12594" href="/z/d/drug information/12594.html" rel="external">
          methohexital
         </a>
         is given IV or PR and thiopental is given PR.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Respiratory depression or apnea occurs in approximately 2 to 11 percent of children who undergo sedation with short-acting barbiturates [
         <a href="#rid65">
          65-70
         </a>
         ]. The risk of respiratory depression is lowest with
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         and highest with rectal thiopental. The potential for airway compromise increases when barbiturates are used in combination with other sedatives and/or opioids [
         <a href="#rid64">
          64
         </a>
         ]. Severe agitation during emergence and prolonged sleepiness or ataxia may occur after pentobarbital administration [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and precautions
         </strong>
         – Use of barbiturates is contraindicated in patients with porphyria. Barbiturates have myocardial depressant effects and should be avoided in patients with hemodynamic instability or heart failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="12594" href="/z/d/drug information/12594.html" rel="external">
          Methohexital
         </a>
         can cause seizures and should be avoided in children with epilepsy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7977221">
         <span class="h2">
          Chloral hydrate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13143" href="/z/d/drug information/13143.html" rel="external">
          Chloral hydrate
         </a>
         was once the preferred sedative agent for diagnostic imaging in infants and children younger than three years of age and is efficacious for that purpose [
         <a href="#rid72">
          72-74
         </a>
         ]. However, small trials and observational studies indicate that chloral hydrate is inferior to other sedation options because of its delayed onset of action, prolonged effect, and high frequency of adverse effects [
         <a href="#rid73">
          73-77
         </a>
         ]. Given the availability of better alternatives, the use of chloral hydrate is
         <strong>
          no longer
         </strong>
         <strong>
          recommended
         </strong>
         . Also, in many regions, chloral hydrate is no longer available. (See
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications", section on 'No intravenous access'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2152491">
         <span class="h1">
          OTHER AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         is a dissociative sedative that provides effective sedation and analgesia for moderately to severely painful procedures.
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O) is an inhaled anesthetic that provides mild analgesia and effective sedation.
        </p>
        <p class="headingAnchor" id="H2152498">
         <span class="h2">
          Ketamine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         is a phencyclidine (PCP) derivative that acts as a dissociative sedative through binding of the N-methyl-D-aspartate (NMDA) receptor. There is no "sedation continuum," and the effect is either present or absent. It produces a trance-like state and provides sedation, analgesia, amnesia, and immobilization, while usually preserving upper airway muscle tone, airway protective reflexes, and spontaneous breathing [
         <a href="#rid2">
          2,3,78-80
         </a>
         ]. Because of its rapid onset, relatively short duration of action and excellent sedative and analgesic properties, it often is used for brief, painful pediatric procedures such as fracture reduction or laceration repair.
        </p>
        <p>
         Clinical practice guidelines for the use of
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         have been developed [
         <a href="#rid80">
          80,81
         </a>
         ]. When used as part of a carefully developed protocol, ketamine can provide safe and effective sedation and analgesia.
        </p>
        <p>
         The clinical manifestations and management of
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         toxicity (both iatrogenic and from illicit use) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/298.html" rel="external">
          "Ketamine poisoning"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
         – Dosing of
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         when used as the sole agent for pediatric sedation varies by the route of administration:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intravenous
         </strong>
         – The initial intravenous (IV) dose of
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         is 1 to 1.5 mg/kg. For healthy patients without QT prolongation or receiving medications that prolong the QT interval, we suggest premedication with
         <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">
          ondansetron
         </a>
         (0.15 mg/kg IV, maximum single dose 4 mg) prior to ketamine to reduce vomiting.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A repeat dose of 0.5 to 1 mg/kg may be administered after 10 minutes as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Intravenous dosing for
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         when combined with
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         (sometimes called ketofol) is provided separately. (See
         <a class="local">
          'Ketamine with propofol (ketofol)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intramuscular
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         may also be given intramuscularly (IM) in an initial dose of 4 to 5 mg/kg with a repeated IM dose of 2 to 4 mg/kg after 10 minutes as needed. However, IM administration is associated with more vomiting and significantly longer recovery times compared with IV administration [
         <a href="#rid82">
          82,83
         </a>
         ]. Thus, in children who are receiving procedural sedation with ketamine and have readily available vascular access, we recommend IV administration rather than IM injection. Although IM ketamine was associated with a greater risk of laryngospasm in one large observational study [
         <a href="#rid80">
          80
         </a>
         ], this finding has been inconsistent and not replicated in two additional studies with larger sample sizes [
         <a href="#rid84">
          84,85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While children routinely receive IV or IM
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         for dissociative sedation for painful procedures, intranasal (IN) ketamine alone has not been shown to reliably achieve this depth of sedation due to the high dose required for effect [
         <a href="#rid86">
          86,87
         </a>
         ]. Further study is required before recommendations for IN ketamine, either alone or in combination with other sedatives, may be made. (See
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications", section on 'Sedation for other nonpainful procedures'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coadministration with opioid analgesia
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         has powerful analgesic properties, and coadministration with opioids is not required or recommended to provide analgesia during a painful procedure. However, administration of opioids for preprocedural analgesia is
         <strong>
          not
         </strong>
         a contraindication to using ketamine sedation. In one large cohort of almost 6300 children receiving emergency department sedation, the addition of
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         to ketamine for procedural sedation was associated with an increased risk of serious adverse events compared with ketamine sedation alone (4.1 versus 0.4 percent, adjusted odds ratio [OR] 4.0, 95% CI 1.8-8.1) [
         <a href="#rid88">
          88
         </a>
         ]. In this study, preprocedural opioid administration was associated with a significantly increased risk of vomiting, oxygen desaturation, and need for significant interventions, but not for serious adverse events. Thus, we continue to advocate for adequately treating pain in children prior to procedural sedation and emphasize that, in doing so, we must recognize that adverse events may occur more frequently.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Premedication with other agents
         </strong>
         – Although administration of
         <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">
          atropine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13338" href="/z/d/drug information/13338.html" rel="external">
          glycopyrrolate
         </a>
         may reduce the amount of salivation, evidence suggests that these medications do
         <strong>
          not
         </strong>
         reduce the risk of laryngospasm and, thus, are
         <strong>
          not
         </strong>
         routinely necessary [
         <a href="#rid89">
          89-91
         </a>
         ]. Similarly, based on the evidence, we do
         <strong>
          not
         </strong>
         recommend the routine use of
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         premedication when
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         alone is administered for procedural sedation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anticholinergic agents – In one prospective study, only one of 947 children receiving
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         without an anticholinergic agent experienced an adverse event that was felt to be due to hypersalivation (brief oxygen desaturation, estimated incidence 0.1 percent, 95% CI 0.0-0.6 percent) [
         <a href="#rid90">
          90
         </a>
         ]. In a systematic review of 8282 ketamine sedations performed in the emergency department and reported in 32 studies, children who received no anticholinergic agent had airway and respiratory adverse events in 3 percent of sedations compared with 3 and 6 percent of patients who received
         <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">
          atropine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13338" href="/z/d/drug information/13338.html" rel="external">
          glycopyrrolate
         </a>
         , respectively [
         <a href="#rid91">
          91
         </a>
         ]. No differences in laryngospasm or apnea were found among the three groups. In a prospective, multicenter, observational study of over 7000 children undergoing sedation with ketamine and
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         , the use of anticholinergic agents was associated with significant increases in adverse events, including serious adverse events (eg, airway obstruction, emergency airway, and laryngospasm) compared with ketamine and propofol alone (12 versus 4 percent, respectively; adjusted OR for serious adverse events 3.2; 95% CI 2.4-4.2) [
         <a href="#rid84">
          84
         </a>
         ]. Taken together, this observational evidence indicates that anticholinergic agents do not improve the safety of ketamine sedation and may increase the risk of adverse events. However, this evidence does not preclude a benefit of anticholinergic agents for selected patients with markedly excessive secretions at baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         – Premedication with midazolam was once thought to minimize the side effects of
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         sedation, especially vomiting and unpleasant recovery reactions (also called emergence phenomenon or agitation). However, it does not appear to be more efficacious than
         <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">
          ondansetron
         </a>
         for vomiting and has not been shown to impact the frequency of emergence phenomenon [
         <a href="#rid3">
          3
         </a>
         ]. As an example, in one randomized trial, 266 children between the ages of 5 months and 16 years received ketamine sedation with or without midazolam [
         <a href="#rid92">
          92
         </a>
         ]. Sedation was equally effective, and emergence phenomena (hallucinations, nightmares, and severe agitation) were similar with the two regimens. Although midazolam premedication was associated with decreased vomiting (9.6 versus 19.4 percent) when compared with ketamine alone, it was also associated with an increased frequency of oxygen desaturation (7.3 versus 1.6 percent, respectively), especially in children younger than 10 years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a separate large, prospective, observational study of children undergoing sedation with
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         , coadministration of benzodiazepines was associated with fewer adverse events such as self-limited oxygen desaturation and serious adverse events (eg, airway obstruction requiring advanced airway management) [
         <a href="#rid84">
          84
         </a>
         ]. These contradictory findings may be due to patient selection and the dosing regimens (as well as polypharmacy) applied in these studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Side effects of
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         include vomiting, unpleasant recovery reactions, and rarely, apnea or laryngospasm [
         <a href="#rid2">
          2,3,22
         </a>
         ]. Hallucinations are most common in patients older than 15 years of age. Although apnea and laryngospasm occur in &lt;1 percent of children who receive ketamine and can generally be managed with positive pressure bag-mask ventilation, it is essential that providers be prepared to rapidly identify and manage this severe complication [
         <a href="#rid85">
          85,93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We suggest that children receiving
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         sedation receive premedication with
         <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">
          ondansetron
         </a>
         or other serotonin receptor antagonists to reduce the frequency of vomiting. Ondansetron effectively reduces emesis after ketamine administration, especially in children younger than five years of age. As an example, in a blinded, randomized trial of 255 children receiving ketamine sedation, premedication with ondansetron reduced the absolute risk of vomiting in the emergency department from 13 to 5 percent (number needed to treat: 13) [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several studies of
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         sedation in children best inform our understanding of associated adverse events and risks. In an individual patient data meta-analysis of 32 studies consisting of over 8000 patients who received sedation in the emergency department, primarily for fracture reduction or wound repair, use of ketamine was associated with the following adverse events [
         <a href="#rid95">
          95,96
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Respiratory events
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Apnea: 0.8 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Laryngospasm: 0.8 percent
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Aspiration: None reported (estimated upper limit of the 95% CI 0.04 percent)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Oxygen desaturation ≤90 percent or upper airway obstruction: 2.8 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Airway and respiratory events were independently associated with age younger than 2 years or older than 12 years, high IV dosing (≥2.5 mg/kg initial dose or total dose ≥5 mg/kg), and coadministration of a benzodiazepine (eg,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         ) or an anticholinergic agent (eg,
         <a class="drug drug_pediatric" data-topicid="12875" href="/z/d/drug information/12875.html" rel="external">
          atropine
         </a>
         ) [
         <a href="#rid96">
          96
         </a>
         ]. Thus, attention to dosing and avoidance of coadministration of midazolam or atropine may result in a lower risk of respiratory events.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vomiting: 8 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Vomiting was independently associated with high IV dosing (≥2.5 mg/kg or total dose ≥5 mg/kg), IM administration, and older age [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recovery agitation requiring specific treatment or described as severe: 1.4 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In an observational study from the Pediatric Sedation Research Consortium, which prospectively examined
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         use for mostly elective procedural sedation in over 22,600 children, the overall incidence of severe adverse events was low. Risk factors found to be associated with increased odds of adverse events were cardiac and gastrointestinal disease, lower respiratory tract infection, and the coadministration of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         and anticholinergics [
         <a href="#rid97">
          97
         </a>
         ]. In a multicenter, prospective, observational study of ketamine sedation of almost 6300 children in six Canadian pediatric emergency departments, serious adverse events and significant interventions were associated with adding propofol or
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         to ketamine. In addition, preprocedural antiemetics were associated with a 50 percent reduction in the odds of vomiting [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although data are limited in children, the combination of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         for procedural sedation appears to provide effective sedation and less vomiting than reported for ketamine alone and less hypotension than described with propofol alone. For example, based on a small observational study and one trial, propofol combined with ketamine was associated with vomiting in 0 to 2 percent of patients and no episodes of hypotension [
         <a href="#rid18">
          18,98
         </a>
         ]. However, adverse respiratory events including laryngospasm can still occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and precautions
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         is contraindicated in patients younger than three months of age, those with psychosis, and those who have had severe adverse reactions in the past  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         is relatively contraindicated in other patients with the following conditions [
         <a href="#rid81">
          81
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Airway instability
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypertension
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Angina or heart failure
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increased intracranial pressure caused by obstructive brain lesions that cause hydrocephalus
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increased intraocular pressure (IOP), such as glaucoma or eye injury
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Porphyria
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thyroid disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence for restricting
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         use in children with possible increased intraocular pressure (IOP) has been conflicting. For example, in two small observational studies of children with healthy eyes undergoing procedural sedation with ketamine, the mean increase in IOP associated with ketamine administration at total doses &lt;4 mg/kg was approximately 1 mmHg [
         <a href="#rid99">
          99,100
         </a>
         ]. However, another series of 60 children with healthy eyes undergoing ketamine sedation with similar dosing found transient increases in IOP &gt;5 mmHg occurring in 25 percent of patients, although the median increase in IOP was modest (3 mmHg [range 0 to 8 mmHg]) [
         <a href="#rid101">
          101
         </a>
         ]. Thus, options other than ketamine are still best for patients with a strong likelihood of increased IOP whenever possible.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3344185873">
         <span class="h3">
          Ketamine with propofol (ketofol)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         (also called "ketofol"), with or without an opioid, are commonly used for procedural sedation and analgesia for children outside of the operating room [
         <a href="#rid84">
          84,88
         </a>
         ]. Ketofol has been proposed as an alternative to either ketamine or propofol alone, which benefits from the positive properties of each drug while mitigating their adverse events [
         <a href="#rid81">
          81,102
         </a>
         ]. The proposed benefit of ketofol is that sub-dissociative dosing of ketamine provides analgesia and sympathomimetic effects, while propofol provides deep sedation and antiemetic effects with a more rapid recovery [
         <a href="#rid102">
          102
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
         – The optimal dosing for ketofol has not been established. One regimen consists of 0.5 mg/kg
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         IV followed by a bolus dose of 0.5 mg/kg of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         . If needed, additional doses of 0.5 mg/kg of propofol may be given every two minutes [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a systematic review of 11 randomized controlled trials, the dosing of ketofol varied and included IV
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         bolus doses of 0.2 to 1 mg/kg and IV
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         initial bolus doses of 0.5 to 2 mg/kg followed by subsequent propofol IV boluses of 0.5 to 1 mg/kg. In some cases, ketamine and propofol were administered individually and in others simultaneously at ketamine to propofol ratios of 1:1, 1:2, 2:1, 1:4 and 1:6 [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Risk of adverse events including apnea, laryngospasm, hypotension, and bradycardia may be higher for patients receiving ketofol compared with
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         alone. In a large, multicenter surveillance study of emergency department procedural sedation, serious adverse events, apnea, laryngospasm, hypotension, and bradycardia were found to be associated with administration of
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         or a combination of ketamine and propofol as compared with ketamine alone [
         <a href="#rid88">
          88
         </a>
         ]. The incidence of serious adverse events in this observational study of 6295 children was low in all groups (ketamine 0.4, propofol 3.7, and ketofol 2.1 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         By contrast, in an unblinded trial of 139 children with cancer undergoing sedation for a lumbar puncture or bone marrow aspiration, the risk of hypotension was lower in patients assigned to ketofol (11 percent) compared with those receiving
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         alone (39 percent) and recovery time was shorter (mean time 8 versus 20 minutes) [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and precautions
         </strong>
         – Contraindications and precautions for ketofol are the same as for both
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         as described separately. (See
         <a class="local">
          'Ketamine'
         </a>
         above and
         <a class="local">
          'Propofol'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Although evidence is limited, when used by experienced providers, ketofol appears to be safe and effective and may result in less vomiting than sedation with
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         alone and less hypotension and a shorter recovery time than sedation with
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         alone [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ketofol versus
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         alone – In one randomized controlled trial of 136 children comparing ketofol 1:1 to ketamine alone for emergency department orthopedic reduction, no difference in efficacy or airway complications was detected [
         <a href="#rid18">
          18
         </a>
         ]. Patients who received ketofol demonstrated slightly faster recoveries (10 versus 12 minutes, difference -2 minutes; 95% CI -4 to -1 minute) and less vomiting (2 versus 12 percent, difference -10 percent; 95% CI -18 to -2 percent). No significant differences in cardiovascular or respiratory adverse events or unpleasant emergency reactions were found between 96 children who received either ketamine alone or ketofol in a second randomized controlled trial [
         <a href="#rid105">
          105
         </a>
         ]. Median recovery time was the same, and although satisfaction scores for providers and nurses were higher in the ketamine alone group, parents or caregivers were equally satisfied with both sedation regimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ketofol compared with
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         alone – As previously mentioned, children with cancer receiving ketofol had less hypotension and shorter recovery times in one unblinded trial [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2152505">
         <span class="h2">
          Nitrous oxide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhaled N
         <sub>
          2
         </sub>
         O is an anesthetic gas that provides mild analgesia, sedation, amnesia, and anxiolysis [
         <a href="#rid106">
          106-108
         </a>
         ]. Spontaneous respirations, airway protective reflexes, and hemodynamic status are generally preserved at concentrations typically used for sedation and analgesia (50 to 70 percent N
         <sub>
          2
         </sub>
         O).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration
         </strong>
         – Onset of sedation and recovery is very rapid with N
         <sub>
          2
         </sub>
         O. N
         <sub>
          2
         </sub>
         O is mixed with 30 to 50 percent oxygen and delivered through a demand-valve mask or continuous flow system [
         <a href="#rid109">
          109
         </a>
         ]. Because the demand-valve mask requires cooperation and may be difficult to activate by smaller children, N
         <sub>
          2
         </sub>
         O
         <sub>
         </sub>
         is used primarily in patients older than four years of age. Continuous delivery systems (a mask strapped over the nose and/or mouth) have been used in younger children with variable success [
         <a href="#rid110">
          110,111
         </a>
         ]. This system is more frequently associated with emesis than the demand-valve technique [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Delivery systems include those that provide a fixed concentration of N
         <sub>
          2
         </sub>
         O with oxygen (typically 50 percent of each) or wall-mounted piped N
         <sub>
          2
         </sub>
         O and oxygen that permits increasing concentrations of N
         <sub>
          2
         </sub>
         O from 0 to 70 percent [
         <a href="#rid112">
          112,113
         </a>
         ]. Essential safety features include the following [
         <a href="#rid109">
          109,113
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Automatic cutoff of N
         <sub>
          2
         </sub>
         O if oxygen delivery fails
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Emergency oxygen override
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maximum N
         <sub>
          2
         </sub>
         O
         <sub>
         </sub>
         delivery limit of 70 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Color-coded tanks with different pin assemblies to attach to the delivery system so that practitioners cannot mistake an N
         <sub>
          2
         </sub>
         O tank for an oxygen tank
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Proportional delivery of N
         <sub>
          2
         </sub>
         O with oxygen
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recovery of patients with a high concentration of oxygen (oxygen washout) to prevent diffusion hypoxia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adequate scavenger systems to prevent excessive occupational exposure to medical personnel
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – N
         <sub>
          2
         </sub>
         O
         <sub>
         </sub>
         has an excellent safety profile for sedation in children with no major cardiopulmonary events (eg, apnea, significant hypoxia, bradycardia, or hypotension) reported in several large observational studies [
         <a href="#rid109">
          109
         </a>
         ]. Minor adverse effects include nausea, vomiting, and dysphoria. Of these, vomiting (up to 7 percent of patients) is most frequently reported [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Deaths have been rarely associated with mechanical failure of the delivery system and inadvertent administration of 100 percent N
         <sub>
          2
         </sub>
         O
         <sub>
         </sub>
         [
         <a href="#rid109">
          109
         </a>
         ]. Thus, clinicians must know how to test and use the equipment in use in their facility. In addition, equipment must be carefully maintained and periodically tested to ensure adequate safety.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and precautions
         </strong>
         – Contraindications to N
         <sub>
          2
         </sub>
         O include nausea and vomiting; trapped gas within body cavities (eg, bowel obstruction, pneumothorax, middle ear infection), especially with the use of concentrations &gt;50 percent; and pregnancy (increased risk of spontaneous abortion) [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Furthermore, potentially pregnant medical personnel should not participate in N
         <sub>
          2
         </sub>
         O administration [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Deeper sedation than anticipated can occur with prolonged inhalation and when N
         <sub>
          2
         </sub>
         O
         <sub>
         </sub>
         is combined with opioids or benzodiazepines [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7977256">
         <span class="h1">
          ANALGESIC AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H659643211">
         <span class="h2">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Appropriate analgesia can often lower the amount of sedative agent needed to provide adequate sedation and thus increase the safety of the procedure. The need for supplementary analgesia varies by the agents used:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         has both sedative and analgesic properties and can thus be used alone to provide sedation for painful procedures. (See
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications", section on 'Approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          Dexmedetomidine
         </a>
         and
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O) have limited analgesic properties that may be inadequate and warrant additional analgesic medications for moderately or severely painful procedures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          Midazolam
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         , do
         <strong>
          not
         </strong>
         have analgesic properties and need to be combined with other analgesic agents.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H223294">
         <span class="h2">
          Topical, local, and regional anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local anesthetics can be delivered topically or by direct infiltration to diminish or abolish the pain associated with many procedures including intravenous (IV) cannula insertion, lumbar puncture, abscess drainage, or laceration repair. The topical anesthetic most frequently used for laceration repair is the combination of
         <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">
          lidocaine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12828" href="/z/d/drug information/12828.html" rel="external">
          tetracaine
         </a>
         (LET), which becomes effective in approximately 30 minutes. For intact skin, EMLA (a eutectic mixture of
         <a class="drug drug_pediatric" data-topicid="12553" href="/z/d/drug information/12553.html" rel="external">
          lidocaine-prilocaine
         </a>
         in a cream base) and LMX 4 (a nonprescription 4 percent liposomal lidocaine preparation) are also effective topical agents. They are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6338.html" rel="external">
          "Clinical use of topical anesthetics in children", section on 'Lidocaine-prilocaine'
         </a>
         .)
        </p>
        <p>
         Local infiltration is typically performed using
         <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">
          lidocaine
         </a>
         . A variety of techniques may be used to decrease the pain of infiltration. (See
         <a class="medical medical_review" href="/z/d/html/6324.html" rel="external">
          "Subcutaneous infiltration of local anesthetics", section on 'Methods to decrease injection pain'
         </a>
         .)
        </p>
        <p>
         Regional anesthesia is also an effective means of procedural analgesia and includes techniques such as digital  (
         <a class="graphic graphic_picture graphicRef50533" href="/z/d/graphic/50533.html" rel="external">
          picture 1
         </a>
         ), dorsal penile  (
         <a class="graphic graphic_figure graphicRef79052" href="/z/d/graphic/79052.html" rel="external">
          figure 1
         </a>
         ), facial nerve  (
         <a class="graphic graphic_figure graphicRef64720" href="/z/d/graphic/64720.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_figure graphicRef77549" href="/z/d/graphic/77549.html" rel="external">
          figure 3
         </a>
         ), and Bier blocks. The procedures for performing these blocks are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/262.html" rel="external">
          "Digital nerve block"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13875.html" rel="external">
          "Assessment and management of facial lacerations", section on 'Facial nerve blocks'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/399.html" rel="external">
          "Overview of anesthesia", section on 'Intravenous regional anesthesia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6326.html" rel="external">
          "Management of zipper entrapment injuries", section on 'Dorsal penile block'
         </a>
         .)
        </p>
        <p>
         When local or regional anesthesia is used, sedation may also be provided to reduce pain and anxiety associated with performing local or regional anesthetic infiltration. Once successful pain control is achieved by local or regional anesthesia, requirements for additional procedural sedation (eg, additional doses or increased depth of sedation) are usually markedly reduced when compared with performing procedural sedation alone.
        </p>
        <p class="headingAnchor" id="H223302">
         <span class="h2">
          Oral sucrose
         </span>
         <span class="headingEndMark">
          —
         </span>
         Much of the research that has evaluated oral
         <a class="drug drug_pediatric" data-topicid="16103" href="/z/d/drug information/16103.html" rel="external">
          sucrose
         </a>
         for pain relief has occurred in preterm and term neonates. In this population, oral sucrose and other sweet-tasting liquids, such as glucose or saccharin, appear to be effective analgesics for minor procedures (eg, heel lancing). (See
         <a class="medical medical_review" href="/z/d/html/5018.html" rel="external">
          "Management and prevention of pain in neonates", section on 'Oral sucrose and other sweet liquids'
         </a>
         .)
        </p>
        <p>
         The influence of factors such as age, type of painful procedure, location in which the procedure is performed, and intercurrent illness on the analgesic effect of
         <a class="drug drug_pediatric" data-topicid="16103" href="/z/d/drug information/16103.html" rel="external">
          sucrose
         </a>
         is uncertain. Nevertheless, sucrose appears to be safe and is easy to administer. A procedure for the administration of sucrose analgesia is described in the table  (
         <a class="graphic graphic_table graphicRef76111" href="/z/d/graphic/76111.html" rel="external">
          table 4
         </a>
         ). The dosing of oral sucrose in term and preterm neonates is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5018.html" rel="external">
          "Management and prevention of pain in neonates", section on 'Oral sucrose and other sweet liquids'
         </a>
         .)
        </p>
        <p>
         In older infants, oral
         <a class="drug drug_pediatric" data-topicid="16103" href="/z/d/drug information/16103.html" rel="external">
          sucrose
         </a>
         also appears effective:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of randomized controlled trials that studied the use of
         <a class="drug drug_pediatric" data-topicid="16103" href="/z/d/drug information/16103.html" rel="external">
          sucrose
         </a>
         or glucose for control of pain prior to immunization in infants 1 to 12 months of age found significant reductions in the incidence and duration of crying [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial in a pediatric emergency department described infants younger than 90 days who received
         <a class="drug drug_pediatric" data-topicid="16103" href="/z/d/drug information/16103.html" rel="external">
          sucrose
         </a>
         prior to bladder catheterization [
         <a href="#rid115">
          115
         </a>
         ]. The analgesic effect of sucrose was only significant among infants 30 days of age or younger.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H223310">
         <span class="h2">
          Fentanyl
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          Fentanyl
         </a>
         is a synthetic opioid that has 75 to 125 times the potency of
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         and provides analgesia for procedures with moderate to severe pain [
         <a href="#rid64">
          64,116
         </a>
         ]. Its rapid onset (within two to three minutes), relatively short duration of action (30 to 60 minutes), and lack of histamine release render it preferable for procedural sedation when compared with longer-acting opioids such as morphine [
         <a href="#rid2">
          2,116
         </a>
         ]. Morphine is an acceptable alternative if fentanyl is not available but has a longer onset and duration of action (20 minutes and 4 hours, respectively). (See
         <a class="medical medical_review" href="/z/d/html/6254.html" rel="external">
          "Pain in children: Approach to pain assessment and overview of management principles", section on 'Opioids'
         </a>
         .)
        </p>
        <p>
         Initial dosing of
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         may need to be adjusted for patients who have tolerance to opioids (eg, patients receiving chronic opioid analgesia). (See
         <a class="medical medical_review" href="/z/d/html/6254.html" rel="external">
          "Pain in children: Approach to pain assessment and overview of management principles", section on 'Initial dosing'
         </a>
         .)
        </p>
        <p>
         Hypoxemia, respiratory depression, and apnea may occur when
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         is combined with other sedatives (eg,
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         ) [
         <a href="#rid25">
          25,52,58
         </a>
         ]. Chest wall and glottic rigidity is a rare but life-threatening adverse effect of fentanyl [
         <a href="#rid117">
          117,118
         </a>
         ]. This muscle rigidity results in inability to ventilate the patient, even after endotracheal intubation. Although widely thought to primarily occur when large doses (eg, &gt;4 mcg/kg) of fentanyl are given rapidly, perioperative chest wall rigidity has been reported in neonates, infants, and young children with single doses of fentanyl as low as 1 mcg/kg [
         <a href="#rid118">
          118
         </a>
         ]. In addition to
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         administration, neuromuscular blockade and endotracheal intubation may be needed to alleviate these symptoms.
        </p>
        <p>
         Although typically administered parenterally,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         also can be effective when used intranasally or via nebulizer, as demonstrated in the following reports:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial, intranasal
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         (as compared with IV
         <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">
          morphine
         </a>
         ) provided effective analgesia for children with long bone fractures [
         <a href="#rid119">
          119
         </a>
         ]. Initial pain control in patients with moderate to severe pain can be achieved within one to two minutes with intranasal fentanyl delivered by an atomizer (2 mcg/kg; maximum single dose 100 mcg) [
         <a href="#rid57">
          57,120-122
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a small randomized trial, nebulized
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         was as effective as IV fentanyl for pain relief among children who presented to an emergency department with painful conditions [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3091572428">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/126190.html" rel="external">
          "Society guideline links: Procedural sedation in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H573733">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Agents and dosing
         </strong>
         – The properties of commonly used agents for pediatric procedural sedation are discussed in this topic and summarized in the tables  (
         <a class="graphic graphic_table graphicRef83512" href="/z/d/graphic/83512.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef83889" href="/z/d/graphic/83889.html" rel="external">
          table 2
         </a>
         ). Assessment, preparation, and proper performance of pediatric procedural sedation outside of the operating room, including selection of medications for pediatric procedural sedation, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16900.html" rel="external">
          "Procedural sedation in children: Preparation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">
          "Procedural sedation in children: Approach"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sedative-hypnotic agents
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          Propofol
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         , and short-acting barbiturates (eg,
         <a class="drug drug_pediatric" data-topicid="12693" href="/z/d/drug information/12693.html" rel="external">
          pentobarbital
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12594" href="/z/d/drug information/12594.html" rel="external">
          methohexital
         </a>
         ) provide sedation but do
         <strong>
          not
         </strong>
         provide analgesia.
         <a class="drug drug_pediatric" data-topicid="13143" href="/z/d/drug information/13143.html" rel="external">
          Chloral hydrate
         </a>
         is inferior to other sedation options because of its delayed onset of action, prolonged effect, and high frequency of adverse effects. (See
         <a class="local">
          'Sedative-hypnotic agents'
         </a>
         above and
         <a class="local">
          'Chloral hydrate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ketamine
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         is a phencyclidine (PCP) derivative that acts as a dissociative sedative through binding of the N-methyl-D-aspartate (NMDA) receptor and is an effective single agent for sedation of children undergoing moderately to severely painful procedures. In children who are receiving procedural sedation with ketamine, intravenous (IV) administration is preferred. (See
         <a class="local">
          'Ketamine'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications", section on 'Moderately or severely painful procedures'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Side effects of
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          ketamine
         </a>
         include increased vomiting, unpleasant recovery reactions, and rarely, apnea or laryngospasm. For healthy patients without QT prolongation or receiving medications that prolong the QT interval and undergoing sedation with ketamine as the sole agent, we suggest premedication with
         <a class="drug drug_pediatric" data-topicid="12659" href="/z/d/drug information/12659.html" rel="external">
          ondansetron
         </a>
         to reduce the frequency of vomiting rather than no premedication (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Ketamine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Analgesia
         </strong>
         – When providing sedation for painful procedures, addition of analgesia lowers the amount of sedative agent needed to provide adequate sedation and thus increases the safety of the procedure. The need for supplementary analgesia varies by the agents used (see
         <a class="local">
          'Analgesic agents'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13398" href="/z/d/drug information/13398.html" rel="external">
          Ketamine
         </a>
         – Ketamine has both sedative and analgesic properties and can thus be used alone to provide sedation for painful procedures. (See
         <a class="local">
          'Ketamine'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/85542.html" rel="external">
          "Procedural sedation in children: Selection of medications", section on 'Approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13128" href="/z/d/drug information/13128.html" rel="external">
          Dexmedetomidine
         </a>
         <strong>
          or
         </strong>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         – Dexmedetomidine or nitrous oxide (N
         <sub>
          2
         </sub>
         O) have limited analgesic properties that may be inadequate and warrant additional analgesic medications for moderately or severely painful procedures. (See
         <a class="local">
          'Dexmedetomidine'
         </a>
         above and
         <a class="local">
          'Nitrous oxide'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12741" href="/z/d/drug information/12741.html" rel="external">
          Propofol
         </a>
         <strong>
          ,
         </strong>
         <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">
          etomidate
         </a>
         <strong>
          , or
         </strong>
         <a class="drug drug_pediatric" data-topicid="12611" href="/z/d/drug information/12611.html" rel="external">
          midazolam
         </a>
         – Propofol, etomidate, and midazolam do
         <strong>
          not
         </strong>
         have analgesic properties and need to be combined with other analgesic agents (eg, local or regional anesthesia or
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         ) to provide effective sedation for painful procedures. (See
         <a class="local">
          'Propofol'
         </a>
         above and
         <a class="local">
          'Etomidate'
         </a>
         above and
         <a class="local">
          'Midazolam'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Topical, local, and regional anesthesia or systemic opioids (eg,
         <a class="drug drug_pediatric" data-topicid="13298" href="/z/d/drug information/13298.html" rel="external">
          fentanyl
         </a>
         ) are the medications most commonly combined with sedative-hypnotic agents to provide procedural sedation for moderately to severely painful procedures. (See
         <a class="local">
          'Analgesic agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Oral
         <a class="drug drug_pediatric" data-topicid="16103" href="/z/d/drug information/16103.html" rel="external">
          sucrose
         </a>
         is suggested to decrease the pain response to minor procedures (eg, heel lancing or immunization administration) in infants younger than one year of age. (See
         <a class="local">
          'Analgesic agents'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5018.html" rel="external">
          "Management and prevention of pain in neonates", section on 'Oral sucrose and other sweet liquids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H343210268">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Deborah C Hsu, MD, MEd, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kennedy RM, Luhmann JD. Pharmacological management of pain and anxiety during emergency procedures in children. Paediatr Drugs 2001; 3:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet 2006; 367:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahyoun C, Krauss B. Clinical implications of pharmacokinetics and pharmacodynamics of procedural sedation agents in children. Curr Opin Pediatr 2012; 24:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin TM, Nicolson SC, Bargas MS. Propofol anesthesia reduces emesis and airway obstruction in pediatric outpatients. Anesth Analg 1993; 76:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pepperman ML, Macrae D. A comparison of propofol and other sedative use in paediatric intensive care in the United Kingdom. Paediatr Anaesth 1997; 7:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vespasiano M, Finkelstein M, Kurachek S. Propofol sedation: intensivists' experience with 7304 cases in a children's hospital. Pediatrics 2007; 120:e1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cravero JP, Blike GT, Beach M, et al. Incidence and nature of adverse events during pediatric sedation/anesthesia for procedures outside the operating room: report from the Pediatric Sedation Research Consortium. Pediatrics 2006; 118:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cravero JP, Beach ML, Blike GT, et al. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium. Anesth Analg 2009; 108:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallory MD, Baxter AL, Yanosky DJ, et al. Emergency physician-administered propofol sedation: a report on 25,433 sedations from the pediatric sedation research consortium. Ann Emerg Med 2011; 57:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiaretti A, Benini F, Pierri F, et al. Safety and efficacy of propofol administered by paediatricians during procedural sedation in children. Acta Paediatr 2014; 103:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emrath ET, Stockwell JA, McCracken CE, et al. Provision of deep procedural sedation by a pediatric sedation team at a freestanding imaging center. Pediatr Radiol 2014; 44:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller KA, Andolfatto G, Miner JR, et al. Clinical Practice Guideline for Emergency Department Procedural Sedation With Propofol: 2018 Update. Ann Emerg Med 2019; 73:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kost S, Roy A. Procedural sedation and analgesia in the pediatric emergency department: a review of sedative pharmacology. Clin Pediatr Emerg Med 2010; 11:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagoshi M, Reddy S, Bell M, et al. Low-dose dexmedetomidine as an adjuvant to propofol infusion for children in MRI: A double-cohort study. Paediatr Anaesth 2018; 28:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinson AE, Peyton J, Kordun A, et al. Trends in Pediatric MRI sedation/anesthesia at a tertiary medical center over time. Paediatr Anaesth 2021; 31:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boriosi JP, Eickhoff JC, Klein KB, Hollman GA. A retrospective comparison of propofol alone to propofol in combination with dexmedetomidine for pediatric 3T MRI sedation. Paediatr Anaesth 2017; 27:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heard C, Burrows F, Johnson K, et al. A comparison of dexmedetomidine-midazolam with propofol for maintenance of anesthesia in children undergoing magnetic resonance imaging. Anesth Analg 2008; 107:1832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah A, Mosdossy G, McLeod S, et al. A blinded, randomized controlled trial to evaluate ketamine/propofol versus ketamine alone for procedural sedation in children. Ann Emerg Med 2011; 57:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srinivasan M, Turmelle M, Depalma LM, et al. Procedural sedation for diagnostic imaging in children by pediatric hospitalists using propofol: analysis of the nature, frequency, and predictors of adverse events and interventions. J Pediatr 2012; 160:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Krauss B. Propofol in emergency medicine: pushing the sedation frontier. Ann Emerg Med 2003; 42:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothermel LK. Newer pharmacologic agents for procedural sedation of children in the emergency department-etomidate and propofol. Curr Opin Pediatr 2003; 15:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassett KE, Anderson JL, Pribble CG, Guenther E. Propofol for procedural sedation in children in the emergency department. Ann Emerg Med 2003; 42:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coté CJ, Notterman DA, Karl HW, et al. Adverse sedation events in pediatrics: a critical incident analysis of contributing factors. Pediatrics 2000; 105:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamond DW. Review article: Safety profile of propofol for paediatric procedural sedation in the emergency department. Emerg Med Australas 2010; 22:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godambe SA, Elliot V, Matheny D, Pershad J. Comparison of propofol/fentanyl versus ketamine/midazolam for brief orthopedic procedural sedation in a pediatric emergency department. Pediatrics 2003; 112:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmoud M, Gunter J, Donnelly LF, et al. A comparison of dexmedetomidine with propofol for magnetic resonance imaging sleep studies in children. Anesth Analg 2009; 109:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmoud M, Radhakrishman R, Gunter J, et al. Effect of increasing depth of dexmedetomidine anesthesia on upper airway morphology in children. Paediatr Anaesth 2010; 20:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmoud M, Jung D, Salisbury S, et al. Effect of increasing depth of dexmedetomidine and propofol anesthesia on upper airway morphology in children and adolescents with obstructive sleep apnea. J Clin Anesth 2013; 25:529.
          </a>
         </li>
         <li class="breakAll">
          Highlights of prescribing information. Precedex, 12/2022 https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021038s028lbl.pdf (Accessed on December 20, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Prescilla R, Fontaine PJ, Zurakowski D. Pediatric CT sedation: comparison of dexmedetomidine and pentobarbital. AJR Am J Roentgenol 2011; 196:W194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Zurakowski D, Zgleszewski SE, et al. High dose dexmedetomidine as the sole sedative for pediatric MRI. Paediatr Anaesth 2008; 18:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Zgleszewski SE, Prescilla R, et al. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. Paediatr Anaesth 2008; 18:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Zurakowski D, Zgleszewski S, et al. Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for pediatric MRI. Paediatr Anaesth 2010; 20:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghai B, Jain K, Saxena AK, et al. Comparison of oral midazolam with intranasal dexmedetomidine premedication for children undergoing CT imaging: a randomized, double-blind, and controlled study. Paediatr Anaesth 2017; 27:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li BL, Ni J, Huang JX, et al. Intranasal dexmedetomidine for sedation in children undergoing transthoracic echocardiography study--a prospective observational study. Paediatr Anaesth 2015; 25:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li BL, Zhang N, Huang JX, et al. A comparison of intranasal dexmedetomidine for sedation in children administered either by atomiser or by drops. Anaesthesia 2016; 71:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poonai N, Spohn J, Vandermeer B, et al. Intranasal Dexmedetomidine for Procedural Distress in Children: A Systematic Review. Pediatrics 2020; 145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahyoun C, Krauss B, Bevacqua M, et al. Safety and Efficacy Associated With a Family-Centered Procedural Sedation Protocol for Children With Autism Spectrum Disorder or Developmental Delay. JAMA Netw Open 2023; 6:e2315974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsze DS, Rogers AP, Baier NM, et al. Clinical Outcomes Associated With Intranasal Dexmedetomidine Sedation in Children. Hosp Pediatr 2023; 13:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talon MD, Woodson LC, Sherwood ER, et al. Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery. J Burn Care Res 2009; 30:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakurai Y, Obata T, Odaka A, et al. Buccal administration of dexmedetomidine as a preanesthetic in children. J Anesth 2010; 24:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karaaslan D, Peker TT, Alaca A, et al. Comparison of buccal and intramuscular dexmedetomidine premedication for arthroscopic knee surgery. J Clin Anesth 2006; 18:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sulton C, McCracken C, Simon HK, et al. Pediatric Procedural Sedation Using Dexmedetomidine: A Report From the Pediatric Sedation Research Consortium. Hosp Pediatr 2016; 6:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lubisch N, Roskos R, Berkenbosch JW. Dexmedetomidine for procedural sedation in children with autism and other behavior disorders. Pediatr Neurol 2009; 41:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carroll CL, Krieger D, Campbell M, et al. Use of dexmedetomidine for sedation of children hospitalized in the intensive care unit. J Hosp Med 2008; 3:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammer GB, Philip BM, Schroeder AR, et al. Prolonged infusion of dexmedetomidine for sedation following tracheal resection. Paediatr Anaesth 2005; 15:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders RD, Xu J, Shu Y, et al. Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology 2009; 110:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Y, Zeng M, Chen W, et al. Dexmedetomidine reduces isoflurane-induced neuroapoptosis partly by preserving PI3K/Akt pathway in the hippocampus of neonatal rats. PLoS One 2014; 9:e93639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkenbosch JW, Tobias JD. Development of bradycardia during sedation with dexmedetomidine in an infant concurrently receiving digoxin. Pediatr Crit Care Med 2003; 4:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammer GB, Drover DR, Cao H, et al. The effects of dexmedetomidine on cardiac electrophysiology in children. Anesth Analg 2008; 106:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Zgleszewski S, Forman RE, et al. An exaggerated hypertensive response to glycopyrrolate therapy for bradycardia associated with high-dose dexmedetomidine. Anesth Analg 2009; 108:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandt MJ, Roback MG, Bajaj L, et al. Etomidate for short pediatric procedures in the emergency department. Pediatr Emerg Care 2012; 28:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baxter AL, Mallory MD, Spandorfer PR, et al. Etomidate versus pentobarbital for computed tomography sedations: report from the Pediatric Sedation Research Consortium. Pediatr Emerg Care 2007; 23:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee-Jayaram JJ, Green A, Siembieda J, et al. Ketamine/midazolam versus etomidate/fentanyl: procedural sedation for pediatric orthopedic reductions. Pediatr Emerg Care 2010; 26:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith D, Cheek H, Denson B, Pruitt CM. Lidocaine Pretreatment Reduces the Discomfort of Intranasal Midazolam Administration: A Randomized, Double-blind, Placebo-controlled Trial. Acad Emerg Med 2017; 24:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiaretti A, Barone G, Rigante D, et al. Intranasal lidocaine and midazolam for procedural sedation in children. Arch Dis Child 2011; 96:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe TR, Braude DA. Intranasal medication delivery for children: a brief review and update. Pediatrics 2010; 126:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy RM, Porter FL, Miller JP, Jaffe DM. Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies. Pediatrics 1998; 102:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massanari M, Novitsky J, Reinstein LJ. Paradoxical reactions in children associated with midazolam use during endoscopy. Clin Pediatr (Phila) 1997; 36:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golparvar M, Saghaei M, Sajedi P, Razavi SS. Paradoxical reaction following intravenous midazolam premedication in pediatric patients - a randomized placebo controlled trial of ketamine for rapid tranquilization. Paediatr Anaesth 2004; 14:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uldum B, Hallonsten AL, Poulsen S. Midazolam conscious sedation in a large Danish municipal dental service for children and adolescents. Int J Paediatr Dent 2008; 18:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shannon M, Albers G, Burkhart K, et al. Safety and efficacy of flumazenil in the reversal of benzodiazepine-induced conscious sedation. The Flumazenil Pediatric Study Group. J Pediatr 1997; 131:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook BA, Bass JW, Nomizu S, Alexander ME. Sedation of children for technical procedures: current standard of practice. Clin Pediatr (Phila) 1992; 31:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coté CJ. Sedation for the pediatric patient. A review. Pediatr Clin North Am 1994; 41:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rooks VJ, Chung T, Connor L, et al. Comparison of oral pentobarbital sodium (nembutal) and oral chloral hydrate for sedation of infants during radiologic imaging: preliminary results. AJR Am J Roentgenol 2003; 180:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Zurakowski D, Connor L, et al. Infant sedation for MR imaging and CT: oral versus intravenous pentobarbital. Radiology 2004; 233:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason KP, Sanborn P, Zurakowski D, et al. Superiority of pentobarbital versus chloral hydrate for sedation in infants during imaging. Radiology 2004; 230:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malviya S, Voepel-Lewis T, Prochaska G, Tait AR. Prolonged recovery and delayed side effects of sedation for diagnostic imaging studies in children. Pediatrics 2000; 105:E42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pomeranz ES, Chudnofsky CR, Deegan TJ, et al. Rectal methohexital sedation for computed tomography imaging of stable pediatric emergency department patients. Pediatrics 2000; 105:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glasier CM, Stark JE, Brown R, et al. Rectal thiopental sodium for sedation of pediatric patients undergoing MR and other imaging studies. AJNR Am J Neuroradiol 1995; 16:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kienstra AJ, Ward MA, Sasan F, et al. Etomidate versus pentobarbital for sedation of children for head and neck CT imaging. Pediatr Emerg Care 2004; 20:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pershad J, Palmisano P, Nichols M. Chloral hydrate: the good and the bad. Pediatr Emerg Care 1999; 15:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macias CG, Chumpitazi CE. Sedation and anesthesia for CT: emerging issues for providing high-quality care. Pediatr Radiol 2011; 41 Suppl 2:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutman MS. Sedation for emergent diagnostic imaging studies in pediatric patients. Curr Opin Pediatr 2009; 21:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olson DM, Sheehan MG, Thompson W, et al. Sedation of children for electroencephalograms. Pediatrics 2001; 108:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg SB, Faerber EN, Aspinall CL, Adams RC. High-dose chloral hydrate sedation for children undergoing MR imaging: safety and efficacy in relation to age. AJR Am J Roentgenol 1993; 161:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litman RS, Soin K, Salam A. Chloral hydrate sedation in term and preterm infants: an analysis of efficacy and complications. Anesth Analg 2010; 110:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Rothrock SG, Lynch EL, et al. Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases. Ann Emerg Med 1998; 31:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Rothrock SG, Harris T, et al. Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases. Acad Emerg Med 1998; 5:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation in children. Ann Emerg Med 2004; 44:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med 2011; 57:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roback MG, Wathen JE, MacKenzie T, Bajaj L. A randomized, controlled trial of i.v. versus i.m. ketamine for sedation of pediatric patients receiving emergency department orthopedic procedures. Ann Emerg Med 2006; 48:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Jeon WC, Park EJ, et al. Adjunctive atropine versus metoclopramide: can we reduce ketamine-associated vomiting in young children? a prospective, randomized, open, controlled study. Acad Emerg Med 2012; 19:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunwell JR, Travers C, Stormorken AG, et al. Pediatric Procedural Sedation Using the Combination of Ketamine and Propofol Outside of the Emergency Department: A Report From the Pediatric Sedation Research Consortium. Pediatr Crit Care Med 2017; 18:e356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melendez E, Bachur R. Serious adverse events during procedural sedation with ketamine. Pediatr Emerg Care 2009; 25:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guthrie AM, Baum RA, Carter C, et al. Use of Intranasal Ketamine in Pediatric Patients in the Emergency Department. Pediatr Emerg Care 2021; 37:e1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsze DS, Steele DW, Machan JT, et al. Intranasal ketamine for procedural sedation in pediatric laceration repair: a preliminary report. Pediatr Emerg Care 2012; 28:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatt M, Johnson DW, Chan J, et al. Risk Factors for Adverse Events in Emergency Department Procedural Sedation for Children. JAMA Pediatr 2017; 171:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinz P, Geelhoed GC, Wee C, Pascoe EM. Is atropine needed with ketamine sedation? A prospective, randomised, double blind study. Emerg Med J 2006; 23:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown L, Christian-Kopp S, Sherwin TS, et al. Adjunctive atropine is unnecessary during ketamine sedation in children. Acad Emerg Med 2008; 15:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Roback MG, Krauss B, Emergency Department Ketamine Meta-analysis Study Group. Anticholinergics and ketamine sedation in children: a secondary analysis of atropine versus glycopyrrolate. Acad Emerg Med 2010; 17:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wathen JE, Roback MG, Mackenzie T, Bothner JP. Does midazolam alter the clinical effects of intravenous ketamine sedation in children? A double-blind, randomized, controlled, emergency department trial. Ann Emerg Med 2000; 36:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Roback MG, Krauss B, Emergency Department Ketamine Meta-Analysis Study Group. Laryngospasm during emergency department ketamine sedation: a case-control study. Pediatr Emerg Care 2010; 26:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langston WT, Wathen JE, Roback MG, Bajaj L. Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial. Ann Emerg Med 2008; 52:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Roback MG, Krauss B, et al. Predictors of emesis and recovery agitation with emergency department ketamine sedation: an individual-patient data meta-analysis of 8,282 children. Ann Emerg Med 2009; 54:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Roback MG, Krauss B, et al. Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children. Ann Emerg Med 2009; 54:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunwell JR, Travers C, McCracken CE, et al. Procedural Sedation Outside of the Operating Room Using Ketamine in 22,645 Children: A Report From the Pediatric Sedation Research Consortium. Pediatr Crit Care Med 2016; 17:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andolfatto G, Willman E. A prospective case series of pediatric procedural sedation and analgesia in the emergency department using single-syringe ketamine-propofol combination (ketofol). Acad Emerg Med 2010; 17:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halstead SM, Deakyne SJ, Bajaj L, et al. The effect of ketamine on intraocular pressure in pediatric patients during procedural sedation. Acad Emerg Med 2012; 19:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drayna PC, Estrada C, Wang W, et al. Ketamine sedation is not associated with clinically meaningful elevation of intraocular pressure. Am J Emerg Med 2012; 30:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wadia S, Bhola R, Lorenz D, et al. Ketamine and intraocular pressure in children. Ann Emerg Med 2014; 64:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green SM, Andolfatto G, Krauss BS. Ketofol for procedural sedation revisited: pro and con. Ann Emerg Med 2015; 65:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiaretti A, Ruggiero A, Barbi E, et al. Comparison of propofol versus propofol-ketamine combination in pediatric oncologic procedures performed by non-anesthesiologists. Pediatr Blood Cancer 2011; 57:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foo TY, Mohd Noor N, Yazid MB, et al. Ketamine-propofol (Ketofol) for procedural sedation and analgesia in children: a systematic review and meta-analysis. BMC Emerg Med 2020; 20:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisz K, Bajaj L, Deakyne SJ, et al. Adverse Events During a Randomized Trial of Ketamine Versus Co-Administration of Ketamine and Propofol for Procedural Sedation in a Pediatric Emergency Department. J Emerg Med 2017; 53:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gamis AS, Knapp JF, Glenski JA. Nitrous oxide analgesia in a pediatric emergency department. Ann Emerg Med 1989; 18:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hennrikus WL, Simpson RB, Klingelberger CE, Reis MT. Self-administered nitrous oxide analgesia for pediatric fracture reductions. J Pediatr Orthop 1994; 14:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanagasundaram SA, Lane LJ, Cavalletto BP, et al. Efficacy and safety of nitrous oxide in alleviating pain and anxiety during painful procedures. Arch Dis Child 2001; 84:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mace SE, Brown LA, Francis L, et al. Clinical policy: Critical issues in the sedation of pediatric patients in the emergency department. Ann Emerg Med 2008; 51:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luhmann JD, Kennedy RM, Porter FL, et al. A randomized clinical trial of continuous-flow nitrous oxide and midazolam for sedation of young children during laceration repair. Ann Emerg Med 2001; 37:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krauss B. Continuous-flow nitrous oxide: searching for the ideal procedural anxiolytic for toddlers. Ann Emerg Med 2001; 37:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babl FE, Oakley E, Seaman C, et al. High-concentration nitrous oxide for procedural sedation in children: adverse events and depth of sedation. Pediatrics 2008; 121:e528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holroyd I. Conscious sedation in pediatric dentistry. A short review of the current UK guidelines and the technique of inhalational sedation with nitrous oxide. Paediatr Anaesth 2008; 18:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison D, Stevens B, Bueno M, et al. Efficacy of sweet solutions for analgesia in infants between 1 and 12 months of age: a systematic review. Arch Dis Child 2010; 95:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers AJ, Greenwald MH, Deguzman MA, et al. A randomized, controlled trial of sucrose analgesia in infants younger than 90 days of age who require bladder catheterization in the pediatric emergency department. Acad Emerg Med 2006; 13:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph MH, Brill J, Zeltzer LK. Pediatric pain relief in trauma. Pediatr Rev 1999; 20:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahnenstich H, Steffan J, Kau N, Bartmann P. Fentanyl-induced chest wall rigidity and laryngospasm in preterm and term infants. Crit Care Med 2000; 28:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewhirst E, Naguib A, Tobias JD. Chest wall rigidity in two infants after low-dose fentanyl administration. Pediatr Emerg Care 2012; 28:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borland M, Jacobs I, King B, O'Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med 2007; 49:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mudd S. Intranasal fentanyl for pain management in children: a systematic review of the literature. J Pediatr Health Care 2011; 25:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saunders M, Adelgais K, Nelson D. Use of intranasal fentanyl for the relief of pediatric orthopedic trauma pain. Acad Emerg Med 2010; 17:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borland M, Milsom S, Esson A. Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial. Emerg Med Australas 2011; 23:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miner JR, Kletti C, Herold M, et al. Randomized clinical trial of nebulized fentanyl citrate versus i.v. fentanyl citrate in children presenting to the emergency department with acute pain. Acad Emerg Med 2007; 14:895.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 82857 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11393327" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Pharmacological management of pain and anxiety during emergency procedures in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16517277" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Procedural sedation and analgesia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22245909" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical implications of pharmacokinetics and pharmacodynamics of procedural sedation agents in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8418715" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Propofol anesthesia reduces emesis and airway obstruction in pediatric outpatients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9188116" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A comparison of propofol and other sedative use in paediatric intensive care in the United Kingdom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18055659" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Propofol sedation: intensivists' experience with 7304 cases in a children's hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16951002" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Incidence and nature of adverse events during pediatric sedation/anesthesia for procedures outside the operating room: report from the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19224786" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21513827" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Emergency physician-administered propofol sedation: a report on 25,433 sedations from the pediatric sedation research consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24138461" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Safety and efficacy of propofol administered by paediatricians during procedural sedation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24859263" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Provision of deep procedural sedation by a pediatric sedation team at a freestanding imaging center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30732981" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinical Practice Guideline for Emergency Department Procedural Sedation With Propofol: 2018 Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Procedural sedation and analgesia in the pediatric emergency department: a review of sedative pharmacology
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29882298" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Low-dose dexmedetomidine as an adjuvant to propofol infusion for children in MRI: A double-cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34036674" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Trends in Pediatric MRI sedation/anesthesia at a tertiary medical center over time.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27779360" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A retrospective comparison of propofol alone to propofol in combination with dexmedetomidine for pediatric 3T MRI sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19020127" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A comparison of dexmedetomidine-midazolam with propofol for maintenance of anesthesia in children undergoing magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20947210" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A blinded, randomized controlled trial to evaluate ketamine/propofol versus ketamine alone for procedural sedation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22177990" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Procedural sedation for diagnostic imaging in children by pediatric hospitalists using propofol: analysis of the nature, frequency, and predictors of adverse events and interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634604" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Propofol in emergency medicine: pushing the sedation frontier.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12640279" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Newer pharmacologic agents for procedural sedation of children in the emergency department-etomidate and propofol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634602" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Propofol for procedural sedation in children in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10742324" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Adverse sedation events in pediatrics: a critical incident analysis of contributing factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20796007" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Review article: Safety profile of propofol for paediatric procedural sedation in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12837876" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Comparison of propofol/fentanyl versus ketamine/midazolam for brief orthopedic procedural sedation in a pediatric emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19690241" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A comparison of dexmedetomidine with propofol for magnetic resonance imaging sleep studies in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20412456" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effect of increasing depth of dexmedetomidine anesthesia on upper airway morphology in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24096043" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effect of increasing depth of dexmedetomidine and propofol anesthesia on upper airway morphology in children and adolescents with obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24096043" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effect of increasing depth of dexmedetomidine and propofol anesthesia on upper airway morphology in children and adolescents with obstructive sleep apnea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21257862" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pediatric CT sedation: comparison of dexmedetomidine and pentobarbital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18363626" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : High dose dexmedetomidine as the sole sedative for pediatric MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18363628" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Hemodynamic effects of dexmedetomidine sedation for CT imaging studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20412458" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for pediatric MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27734549" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Comparison of oral midazolam with intranasal dexmedetomidine premedication for children undergoing CT imaging: a randomized, double-blind, and controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25959165" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Intranasal dexmedetomidine for sedation in children undergoing transthoracic echocardiography study--a prospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26936022" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A comparison of intranasal dexmedetomidine for sedation in children administered either by atomiser or by drops.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31862730" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Intranasal Dexmedetomidine for Procedural Distress in Children: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37252743" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Safety and Efficacy Associated With a Family-Centered Procedural Sedation Protocol for Children With Autism Spectrum Disorder or Developmental Delay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36810939" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical Outcomes Associated With Intranasal Dexmedetomidine Sedation in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19506498" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20175284" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Buccal administration of dexmedetomidine as a preanesthetic in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17175428" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Comparison of buccal and intramuscular dexmedetomidine premedication for arthroscopic knee surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27516413" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pediatric Procedural Sedation Using Dexmedetomidine: A Report From the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19589455" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Dexmedetomidine for procedural sedation in children with autism and other behavior disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18438790" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Use of dexmedetomidine for sedation of children hospitalized in the intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15960649" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prolonged infusion of dexmedetomidine for sedation following tracheal resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19352168" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24743508" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Dexmedetomidine reduces isoflurane-induced neuroapoptosis partly by preserving PI3K/Akt pathway in the hippocampus of neonatal rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12749653" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Development of bradycardia during sedation with dexmedetomidine in an infant concurrently receiving digoxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18165557" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The effects of dexmedetomidine on cardiac electrophysiology in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19224802" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : An exaggerated hypertensive response to glycopyrrolate therapy for bradycardia associated with high-dose dexmedetomidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22929142" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Etomidate for short pediatric procedures in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18090099" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Etomidate versus pentobarbital for computed tomography sedations: report from the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20502386" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Ketamine/midazolam versus etomidate/fentanyl: procedural sedation for pediatric orthopedic reductions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27739142" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Lidocaine Pretreatment Reduces the Discomfort of Intranasal Midazolam Administration: A Randomized, Double-blind, Placebo-controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21030365" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Intranasal lidocaine and midazolam for procedural sedation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20696726" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Intranasal medication delivery for children: a brief review and update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9755272" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9415834" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Paradoxical reactions in children associated with midazolam use during endoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15500492" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Paradoxical reaction following intravenous midazolam premedication in pediatric patients - a randomized placebo controlled trial of ketamine for rapid tranquilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18328049" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Midazolam conscious sedation in a large Danish municipal dental service for children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9386663" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Safety and efficacy of flumazenil in the reversal of benzodiazepine-induced conscious sedation. The Flumazenil Pediatric Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1547584" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Sedation of children for technical procedures: current standard of practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8295806" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Sedation for the pediatric patient. A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12646468" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Comparison of oral pentobarbital sodium (nembutal) and oral chloral hydrate for sedation of infants during radiologic imaging: preliminary results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15516603" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Infant sedation for MR imaging and CT: oral versus intravenous pentobarbital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14699175" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Superiority of pentobarbital versus chloral hydrate for sedation in infants during imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10699144" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prolonged recovery and delayed side effects of sedation for diagnostic imaging studies in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10790471" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Rectal methohexital sedation for computed tomography imaging of stable pediatric emergency department patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7900578" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Rectal thiopental sodium for sedation of pediatric patients undergoing MR and other imaging studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15295244" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Etomidate versus pentobarbital for sedation of children for head and neck CT imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10608336" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Chloral hydrate: the good and the bad.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21847733" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Sedation and anesthesia for CT: emerging issues for providing high-quality care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19381092" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Sedation for emergent diagnostic imaging studies in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11433070" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Sedation of children for electroencephalograms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8352124" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : High-dose chloral hydrate sedation for children undergoing MR imaging: safety and efficacy in relation to age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20032023" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Chloral hydrate sedation in term and preterm infants: an analysis of efficacy and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9624307" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9862587" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15520705" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Clinical practice guideline for emergency department ketamine dissociative sedation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21256625" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17052563" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A randomized, controlled trial of i.v. versus i.m. ketamine for sedation of pediatric patients receiving emergency department orthopedic procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23009186" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Adjunctive atropine versus metoclopramide: can we reduce ketamine-associated vomiting in young children? a prospective, randomized, open, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28650904" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Pediatric Procedural Sedation Using the Combination of Ketamine and Propofol Outside of the Emergency Department: A Report From the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19404223" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Serious adverse events during procedural sedation with ketamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31290798" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Use of Intranasal Ketamine in Pediatric Patients in the Emergency Department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22858745" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Intranasal ketamine for procedural sedation in pediatric laceration repair: a preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28828486" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Risk Factors for Adverse Events in Emergency Department Procedural Sedation for Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16498158" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Is atropine needed with ketamine sedation? A prospective, randomised, double blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18370983" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Adjunctive atropine is unnecessary during ketamine sedation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20370745" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Anticholinergics and ketamine sedation in children: a secondary analysis of atropine versus glycopyrrolate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11097698" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Does midazolam alter the clinical effects of intravenous ketamine sedation in children? A double-blind, randomized, controlled, emergency department trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20944510" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Laryngospasm during emergency department ketamine sedation: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18353503" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Effect of ondansetron on the incidence of vomiting associated with ketamine sedation in children: a double-blind, randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19501426" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Predictors of emesis and recovery agitation with emergency department ketamine sedation: an individual-patient data meta-analysis of 8,282 children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19201064" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27505716" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Procedural Sedation Outside of the Operating Room Using Ketamine in 22,645 Children: A Report From the Pediatric Sedation Research Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20370749" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : A prospective case series of pediatric procedural sedation and analgesia in the emergency department using single-syringe ketamine-propofol combination (ketofol).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23009160" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : The effect of ketamine on intraocular pressure in pediatric patients during procedural sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22169582" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Ketamine sedation is not associated with clinically meaningful elevation of intraocular pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24582603" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Ketamine and intraocular pressure in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25544732" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Ketofol for procedural sedation revisited: pro and con.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21584935" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Comparison of propofol versus propofol-ketamine combination in pediatric oncologic procedures performed by non-anesthesiologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33032544" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Ketamine-propofol (Ketofol) for procedural sedation and analgesia in children: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28433211" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Adverse Events During a Randomized Trial of Ketamine Versus Co-Administration of Ketamine and Propofol for Procedural Sedation in a Pediatric Emergency Department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2916783" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Nitrous oxide analgesia in a pediatric emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8077442" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Self-administered nitrous oxide analgesia for pediatric fracture reductions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11369566" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Efficacy and safety of nitrous oxide in alleviating pain and anxiety during painful procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18359378" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Clinical policy: Critical issues in the sedation of pediatric patients in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11145766" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A randomized clinical trial of continuous-flow nitrous oxide and midazolam for sedation of young children during laceration repair.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11145774" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Continuous-flow nitrous oxide: searching for the ideal procedural anxiolytic for toddlers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18310173" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : High-concentration nitrous oxide for procedural sedation in children: adverse events and depth of sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18095960" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Conscious sedation in pediatric dentistry. A short review of the current UK guidelines and the technique of inhalational sedation with nitrous oxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20463370" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Efficacy of sweet solutions for analgesia in infants between 1 and 12 months of age: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16636358" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : A randomized, controlled trial of sucrose analgesia in infants younger than 90 days of age who require bladder catheterization in the pediatric emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10073069" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Pediatric pain relief in trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10752838" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Fentanyl-induced chest wall rigidity and laryngospasm in preterm and term infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22561320" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Chest wall rigidity in two infants after low-dose fentanyl administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17067720" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21867860" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Intranasal fentanyl for pain management in children: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21175512" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Use of intranasal fentanyl for the relief of pediatric orthopedic trauma pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21489168" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17898251" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Randomized clinical trial of nebulized fentanyl citrate versus i.v. fentanyl citrate in children presenting to the emergency department with acute pain.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
